1 / 70

Common Opportunistic Infections in HIV Patients

Common Opportunistic Infections in HIV Patients. Chris Farnitano, MD Monday, August 31, 2009 Noon Conference. Objectives. Discuss most common opportunistic infections (OIs): Dx and Rx Discuss immune reconstitution disease Review primary OI prophylaxis. Forms.

harva
Download Presentation

Common Opportunistic Infections in HIV Patients

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Common Opportunistic Infections in HIV Patients Chris Farnitano, MD Monday, August 31, 2009 Noon Conference

  2. Objectives • Discuss most common opportunistic infections (OIs): Dx and Rx • Discuss immune reconstitution disease • Review primary OI prophylaxis

  3. Forms

  4. What are the most common OI’s? • Cohort Studies in pre-triple therapy era: • Candida • Pneumocystis Carinii • Cytomegalovirus • Mycobacterium Avium Complex • Pneumocystis - second episode • Toxoplasmi gondii • Herpes zoster

  5. Causes of death, PHC HIV clinic • 2007-9 • RH: Crypto meningitis • TW: street drug overdose • SA: sepsis, pneumonia and massive hemoptysis • DW: metastatic prostate ca • RP: CVA, laryngeal ca • VA: PML (progressive multifocal leukencephalopathy) • AM: bacterial pneumonia, ETOH cirrhosis, wasting

  6. OIs diagnosed, PHC HIV clinic • 2005-9 • PCP pneumonia • Esophageal Candidiasis • Herpes Simplex • Herpes Zoster • M. Kansasii immune reconstitution pneumonia • Mycobacterium Avium Complex (MAC) • Cryptococcal Fungemia, meningitis • Histoplasmosis • PML

  7. Effect of HAART on Opportunistic Infection Incidence • Most OI’s have declined 80-90% • OI’s seen now mostly in 3 groups • undiagnosed HIV+ • not in care or not adhering to therapy • long time “battle-scarred warriors” failing after a long history of multiple regimens

  8. More people living with AIDS

  9. Pyramid or iceberg model

  10. Strata of Pyramid • >350 T Cells • 350-200 • 50-200 • <50

  11. >350 T Cells • Increased incidence of diseases that also affect normal hosts: • Recurrent Vaginal Candidiasis • Pulmonary Tuberculosis • Pnuemococcal Pneumonia • Cervical Dysplasia

  12. Pulmonary TB

  13. 200-350 T Cells: • Herpes Simplex • Herpes Zoster • Thrush

  14. Herpes Zoster (Shingles)

  15. 50-200 T Cells: • Pneumocystis Carinii Pnuemonia • Toxoplasmosis • Cryptococcus

  16. Toxoplasmosis

  17. <50 T Cells • CMV Retinitis • Mycobacterium Avium Complex • Cryptosporidiosis • Progressive Multifocal Leukencephalopathy

  18. PML

  19. Ockham's razor does not apply for advanced AIDS • -often multiple diagnoses present simultaneously • ie PCP, CMV, KS, Cocci • 12% of bacterial pneumonias also have PCP • 10% of PCP pneumonia complicated by bacterial infection • search for second etiology if patient not improving

  20. Immune reconstitution diseases(HAART attacks) • MAC adenitis • CMV • TB • PCP

  21. Primary OI prophylaxis • PCP -T cells <200 or thrush • Toxo -T cells <100 and +Toxo titer • MAC - Tcells <50 • TB – INH x 9 months if PPD >5mm or quantiferon-TB positive

  22. Quantiferon vs. TST in HIV patients • Quantiferon not approved for use in immunocomprimised • 147 HIV patients in New Orleans given both tests: • 36% did not return for TST reading • 15 positive by quantiferon • 1 positive by TST • Quantiferon is more sensitive but without a gold standard for latent TB infection cannot say whether it is more or less specific • Another study showed similar positive test result rates but a better correlation with risk factors for quantiferon vs. TST suggesting quantiferon is a more specific test

  23. Quantiferon vs. TST in HIV patients • “Given the high risk for progression to active disease in HIV-infected persons, any HIV-infected person with reactivity on any of the current LTBI diagnostic tests should be considered infected with M. tuberculosis” • ----CDC guidelines, 3/24/09

  24. PCP Prophylaxis • Septra SS or DS qd or DS TIW • Single strength has similar efficacy with fewer adverse reactions (I.e. late onset rash, hepatotoxicity, fever) • 25-50% of AIDS pts. D/c Septra DS due to reactions • Septra Desensitization: • 1cc qd x 3d, then 2cc qd x 3d, then 5ccqd x 3d, then one SS tab qd • Dapsone 100mg qd +pyramethamine 50mg qweek + leukovorin 25mg qweek • Aerosolized pentamadine 300mg q month • Atavaquone 1500mg qd

  25. Aerosolized pentamidine booth

  26. Toxo prophylaxis • Septra SS or DS qd or DS TIW • Septra Desensitisation: • 1cc qd x 3d, then 2cc qd x 3d, then 5ccqd x 3d, then one SS tab qd • Dapsone 100mg qd +pyramethamine 50mg qweek + leukovorin 25mg qweek • Atovaquone 1500mg qd

  27. MAC prophylaxis • Zithromax 600mg x 2 tabs qweek reduces infection rate 59% • Also seems to reduce risk of PCP

  28. Specific Opportunistic Infections

  29. Case Study: HW • 51 yo male with poor adherence to meds • HIV + since at least 1996 • 1st episode thrush March,2005 • C/o dry mouth • Exam: white patches on buccal mucosa • T Cells 54 • Treated with fluconazole, sx resolve

  30. Case Study: HW • Recurrent thrush July, 2005 • Fluconazole again prescribed • September, 2005 • C/o odynophagia • Dx: probably esophageal candidiasis • Fluconazole again prescribed • Sx resolve in 3 days

  31. Case Study: HW • Recurrent odynophagia January, 2006 • Switched to itraconazole liquid • 3 weeks later: • odynophagia resolved • Thrush persists, resolved on re-exam March, 2006 • August, 2006-March, 2007 • Recurrent episodes of thrush and esophageal candidiasis due to non-adherence to intraconazole • Each episode improves when patient is adherent

  32. Case Study: HW • April, 2007 • Persistent thrush despite stated adherence • Switched to Voriconazole • Sx resolve November, 2007 T Cells 5 Weight 121# (baseline 198#) -recurrent odynophagia despite adherence to voriconazole Admitted for IV Capsofungin Sx markedly improve in 24 hours Fungal Cx: Candida Albicans Sensitivities: resistant to fluconazole, itraconazole and voriconazole

  33. Case Study: HW • December 2007-August 2008 • Persistent extensive thrush • Continued on Voriconazole • T cells 54 -> 12 August 2008: moves in with sisters after hospital stay, adherence improves markedly January 2009: T cells 77, thrush much improved April, 2009: T cells 239, thrush resolved

  34. Candida • Thrush • Angular Chelitis • Vaginal Candidiasis • Esophageal Candidiasis

  35. Thrush • cottage cheese plaques • soft palate, buccal mucosa, tonsils • can be removed with a tongue blade • also erythematous form without exudate

  36. Thrush

  37. Angular chelitis • pain • fissures • erythema • difficulty opening mouth

  38. Angular Chelitis

  39. Recurrent Vaginal Candidiasis • less frequent than you would expect, unless T Cells<100 • can use Fluconazole 200mg qweek for suppression

  40. Esophageal Candidiasis • odynophagia • usually also has thrush (positive predictive value is 90%, but 18% of esophageal candidiasis presents without thrush) • Treat empirically x 5-7 days • if not better, scope to r/o other causes: • CMV, HSV, idopathic esophageal ulcers, lymphoma • Secondary prophylaxis needed

  41. Esophageal Candidiasis

  42. Treatment: • Fluconazole 100-200mg qd until sx resolve • Alternatives for resistant Candida: • Higher dose fluconazole (400-800 mg/d • Itraconazole • Voriconazole • IV Capsofungin • IV Amphotericin

  43. PCP - Who gets it: • Septra prophylaxis highly efficatious • Risk if T Cells <200 or thrush

  44. PCP - Symptoms • insidious onset • 2-4 weeks of progressive symptoms • Fever, sweats, weight loss, fatigue, nonproductive cough • progressive dyspnea • retrosternal discomfort

  45. PCP - Signs • Lung exam usually normal • CXR: bilateral diffuse interstitial infiltrate in 80-90% • LDH>400 in 62% • PO2<75 in 66%

  46. PCP Pneumonia

  47. Severe PCP

  48. PCP - Diagnosis • Induced sputum x 3 in early AM (all on same day): 50-70% sensitive • Bronchoscopy (+/-Bx): 80-90% sensitive • PCR based tests • To collect sputums or go directly to bronch?

  49. PCP - Treatment • Can begin before Dx confirmed without affecting diagnostic yield • Prednisone 40mg BID x 5d. Then taper over total 21d. • Septra 15mgTMP/kg/d IV div. Q8h x 21d. • Switch to po when improved • give first dose prednisone 15-30 minutes before Septra

  50. Approach to HIV patient with Pneumonia • What is the T Cell Count?

More Related